ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2026
Quantifying the population-level impact of insomnia on dementia among older adults in the United States.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sleep architecture and self-reported sleep quality are associated with Alzheimer's disease biomarkers in older adults without dementia.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInsomnia has been identified as a plausible modifiable risk factor for dementia. Quantifying its population-level impact may inform strategies to reduce dementia risk among older adults in the United States.
methodsWe used data from the 2022 National Health and Aging Trends Study (NHATS) to classify insomnia as sleep-onset insomnia, sleep-maintenance insomnia, or both, and to identify probable dementia using established algorithms. We obtained relative risks (RRs) from a published meta-analysis. Using these RRs and NHATS prevalence estimates, we estimated the population attributable fraction (PAF) of dementia cases attributable to insomnia overall and stratified by age and sex.
resultsAmong 5899 participants (44.7% aged ≥80 years; 57.9% females; 77.9% non-Hispanic White), 28.7% (95% CI: 26.9%, 30.5%) reported insomnia symptoms and 6.6% (95% CI: 5.9%, 7.3%) had probable dementia. The estimated PAF of probable dementia due to any insomnia was 12.5% (95% CI: 1.0%, 25.0%), and it was slightly higher among females (13.1%, 95% CI: 1.0%, 26.1%) than males (11.6%, 95% CI: 0.9%, 23.3%). The highest PAF was observed in the 65-69 age group (14.4%, 95% CI: 1.1%, 27.8%) among females and in the 70-74 age group (12.8%, 95% CI: 0.9%, 25.8%) among males. An estimated 449,069 (95% CI: 35 049, 923 082) dementia cases in 2022 could have been prevented if insomnia were eliminated.
conclusionsApproximately 13% of dementia cases, almost half a million cases, among US older adults may be attributable to insomnia. Addressing insomnia could be a promising target for dementia prevention efforts in aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.